Effects of LP28 on Immunity Enhancement in the Elderly

Last updated: December 4, 2024
Sponsor: Synbio Tech Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Common Cold

Acute Rhinitis

Treatment

Placebo Capsule

LP28 capsule

Clinical Study ID

NCT06724185
SF24108C
  • Ages 50-75
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Due to the increasing attention on aging-related health issues, this study focuses on the elderly population as participants. The aim is to investigate whether supplementation with Lactobacillus plantarum LP28 can effectively enhance immunity, reduce the frequency and severity of common cold infections, and ultimately promote overall health in the elderly.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Those who had symptoms of common cold or tonsillitis at least twice in the pastyear.

Exclusion

Exclusion Criteria:

  • People who have liver, kidney, immune, or neoplastic diseases diagnosed by doctor.

  • People with mental illnesses such as schizophrenia or depression.

  • People who have allergic rhinitis.

  • People who have a current condition of drug or alcohol dependence.

  • Any person is deemed inappropriate by the researcher for the clinical trial.

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Placebo Capsule
Phase:
Study Start date:
July 09, 2024
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • National Chung Hsing University

    Taichung, 402202
    Taiwan

    Active - Recruiting

  • Taichung Veterans General Hospital

    Taichung, 407219
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.